Journal article
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
- Abstract:
-
Background: A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×101 50% tissue culture infectious dose (TCID50) pre-alpha SARS-CoV-2 virus. Given the increasing prevalence of seropositivity to SARS-CoV-2, a CHIM that could be used for vaccine development will need to induce infection in those with pre-existing immunity. Our aim was to find a dose of pre-alpha SARS-CoV-2 virus that induced infe...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 675.0KB, Terms of use)
-
- Publisher copy:
- 10.1016/s2666-5247(24)00025-9
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Microbe More from this journal
- Volume:
- 5
- Issue:
- 7
- Pages:
- 655-668
- Publication date:
- 2024-05-01
- Acceptance date:
- 2024-01-18
- DOI:
- EISSN:
-
2666-5247
- Language:
-
English
- Pubs id:
-
1994167
- Local pid:
-
pubs:1994167
- Deposit date:
-
2024-05-02
Terms of use
- Copyright holder:
- Jackson et al.
- Copyright date:
- 2024
- Rights statement:
- © 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Notes:
- For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record